A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).

被引：0
|
作者：
Nand, S [1 ]
Godwin, J [1 ]
White, C [1 ]
Beltran, O [1 ]
Stiff, P [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4649
引用
收藏
页码：214B / 214B
页数：1
相关论文
共 50 条
  • [21] Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia
    Abbi, Kamal K. S.
    Rybka, Witold
    Ehmann, W. Christopher
    Claxton, David F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (01): : 41 - 46
  • [22] A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)
    Palmisiano, Neil
    Jeschke, Grace
    Wilde, Lindsay
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
  • [23] Phase II trial of arsenic trioxide (AS203) in patients (PTS) with relapsed/refractory acute myeloid leukemia (AML), blast crisis of CML, or myelodysplasia (MDS).
    Wiernik, PH
    Dutcher, JP
    Gallagher, R
    Caliendo, G
    Garl, S
    Paietta, E
    BLOOD, 1999, 94 (10) : 510A - 510A
  • [24] Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study
    Silverman, Lewis R.
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Najfeld, Vesna
    Ohnuma, Takao
    Wilhelm, Francois
    Reddy, E. Premkumar
    Holland, James F.
    BLOOD, 2010, 116 (21) : 1214 - 1214
  • [25] Outcome of etoposide and mitoxantrone for relapsed or refractory acute myeloid leukemia (RR-AML) in the modern era.
    Bowman, Zelia Ramone Karema
    Caddell, Ryan James
    Kanate, Abraham Sebastian
    Shillingburg, Alex
    Shah, Nilay Arvind
    Craig, Michael
    Cumpston, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 211B - 211B
  • [27] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
    Klisovic, Rebecca B.
    Wang, Hongyan
    Walker, Alison
    Walsh, Katherine
    Vasu, Sumithira
    Garzon, Ramiro
    Devine, Steven M.
    Wang, Jiang
    Garr, Celia
    Norris, Adam
    Byrd, John C.
    Grever, Michael R.
    Blum, William
    Chan, Kenneth K.
    Marcucci, Guido
    BLOOD, 2012, 120 (21)
  • [28] APhase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
    Advani, Anjali S.
    Cooper, Brenda
    Visconte, Valeria
    Elson, Paul
    Chan, Ricky
    Carew, Jennifer
    Wei, Wei
    Mukherjee, Sudipto
    Gerds, Aaron
    Carraway, Hetty
    Nazha, Aziz
    Hamilton, Betty
    Sobecks, Ronald
    Caimi, Paolo
    Tomlinson, Benjamin
    Malek, Ehsan
    Little, Jane
    Miron, Alexander
    Pink, John
    Maciejewski, Jaroslaw
    Unger, Allison
    Kalaycio, Matt
    de Lima, Marcos
    Sekeres, Mikkael A.
    CLINICAL CANCER RESEARCH, 2019, 25 (14) : 4231 - 4237
  • [29] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Attar, Eyal C.
    Amrein, Philip C.
    Fraser, James W.
    Fathi, Amir T.
    McAfee, Steven
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Stone, Richard M.
    Foster, Julia
    Neuberg, Donna
    Ballen, Karen K.
    LEUKEMIA RESEARCH, 2013, 37 (09) : 1016 - 1020
  • [30] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Amrein, Philip C.
    Attar, Eyal C.
    Fathi, Amir Tahmasb
    McAfee, Steven L.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Foster, Julia
    Stone, Richard M.
    Neuberg, Donna S.
    Ballen, Karen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345